July 20, 2021 7:47am
Very thin trading in month, so far has acerbated pricing movements
Pre-open indications: 6 BUYs: CRSP, EDIT, NTLA, SAGE, PSTI, VYGR; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
I challenge the status quo to achieve what most believe is impossible, each session breaking down tactical ways to earn
Dow futures are UP +0.69% (+233 points), S&P futures are UP +0.55% (+24 point) and NASDAQ futures are UP +0.45% (+65 points)
U.S. stock futures rebounded slightly on Tuesday
European stocks were modestly higher, struggling to rebound
Asia-Pacific stocks were either mixed and falling with markets in Indonesia, Malaysia and Singapore being closed for holidays.
Henry’omics:
- Monday, indexes suffered a sharp sell-off as investors feared that the fast-spreading delta coronavirus variant could hinder the economic recovery.
Monday’s evening’s recap: “to start the week, a crash with blood on the street as sector breadth spilled red following six (6) negative closes in a row and nine (9) of thirteen (13) sessions in July” … https://www.regmedinvestors.com/articles/12008
- The Nasdaq closed DOWN -152.25 points (-1.06%);
- The IBB closed up +0.68% and XBI closed up +0.16%
- Sector volume was LOW with 0 of the 4-upside having higher than the 3-month average volume with very LOW volume of 4 of 30-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +4.05 points or +211.95% at 22.95
- Monday’s percentage (%) of the 4-upside were +1.40% (PSTI) to +2.85% (EDIT) while the 30-downside ranges from -0.10% (SGMO) to -7.57% (MDXG);
Q3/21: 3 positive and 9 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed up +$0.01 to $1.71 with 307 shares traded after Thursday’s -$0.01 to $1.70 with 1,596 shares traded, Wednesday’s +$0.06 to $1.71 with 996 shares traded, Tuesday’s +$0.14 to $1.64 with 1,100 shares traded and last Monday’s flat with 2,600 shares traded.
Question#1: WHAT happens to the future of the company … IF they can NOT exercise the warrants – they are “BROKE” if they do exercise – won’t they will be just “BROKE” by beginning of Q4/21?
Question#2: WHAT is the end game or play-book for this company, it has not done ANYTHING to monetize their asset –a n approved IND … so WHERE is the value proposition?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications: Some of the stocks that were hit the hardest overpast sessions are bouncing in Tuesday’s pre-market …
BUY from SELL:
CRISPR therapeutics (CRSP) closed down -$0.52 to $125.73 after Monday’s -$0.85 to $126.25 and has a positive +$4.15 or +3.30% pre-market indication.
Editas Medicine (EDIT) closed up +$1.21 to $43.60 after Monday’s +$0.40 to $42.39 and Friday’s -$0.72 to $43.08, with a positive +$1.07 or +2.45% pre-market indication.
Intellia Therapeutics (NTLA) closed up +$3.69 to $138.94 after Monday’s -$2.85 to $135.25 and has a positive +$3.06 or +2.29% pre-market indication.
Pluristem (PSTI) closed up +$0.05 to $3.61 after Monday’s $3.56 and last Friday’s $3.79 with a positive +0.06 or +1.66% pre-market indication
Sage Therapeutics (SAGE) closed down -$1.48 to $48.26 after Monday’s $47.74 with a positive +$0.74 or +1.50% pre-market indication.
Voyager therapeutics (VYGR) closed down -$0.06 to $3.35 after Monday’s $3.41 and Friday’s $3.47 with a positive +$0.28 or +8.36% pre-market indication.
The BOTTOM LINE: I also continue to be a skeptic yet, a market move will drag many of the cell and gene therapy equities back to a positive upside, this still being a confused sector as sentiment rages and fades, momentum is usurped and fundamentals were ignored.
Q2 earnings LPS (loss-per-share) release date are soon to be divulged and not positively; yet another – Sage Therapeutics (SAGE) releases “earnings” on 8/3.
It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
